CAR-T cell therapy for relapsed/refractory large B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special cell therapy called CAR-T that targets CD19 on lymphoma cells. It is for people with aggressive large B-cell lymphoma that has not responded to standard treatments or has come back after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large B-cell lymphoma that has a protein called CD19 on the cancer cells (like DLBCL or transformed indolent lymphoma)
- Your lymphoma has either come back after treatment or hasn't responded to at least two types of therapy (including a CD20 antibody and a chemotherapy drug called anthracycline)
- You are 18 years or older and in fairly good health (able to care for yourself)
- Your heart, kidneys, liver, and lungs are working well enough (checked with simple blood tests and scans)
- You have not had a CAR-T cell treatment before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
This trial tests CY-219, a type of cell therapy that trains your immune cells to fight B-cell lymphoma that has come back or stopped responding to standard treatments. The study evaluates whether this approach is safe and effective for patients like you.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.